WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced the U.S.

MORRISTOWN, N.J., and BUDAPEST, HUNGARY, Dec. 16, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) ("Watson") and Gedeon Richter Plc ("Richter") today announced that Watson's subsidiary, Watson Laboratories, Inc.

MORRISTOWN, N.J., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. pilot study evaluating Uracyst® (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

PARIS and MORRISTOWN, N.J., Sept. 17 /PRNewswire-FirstCall/ -- HRA Pharma, a privately-held, European pharmaceutical company that develops healthcare solutions in reproductive health and endocrinology and makes them available worldwide, and Watson Pharmaceuticals, Inc.